KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ionis Pharmaceuticals (IONS) Equity Average (2016 - 2025)

Historic Equity Average for Ionis Pharmaceuticals (IONS) over the last 16 years, with Q3 2025 value amounting to $624.8 million.

  • Ionis Pharmaceuticals' Equity Average rose 3493.16% to $624.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $624.8 million, marking a year-over-year increase of 3493.16%. This contributed to the annual value of $487.5 million for FY2024, which is 161.16% up from last year.
  • Latest data reveals that Ionis Pharmaceuticals reported Equity Average of $624.8 million as of Q3 2025, which was up 3493.16% from $553.7 million recorded in Q2 2025.
  • Ionis Pharmaceuticals' 5-year Equity Average high stood at $740.7 million for Q1 2022, and its period low was $280.1 million during Q2 2024.
  • In the last 5 years, Ionis Pharmaceuticals' Equity Average had a median value of $556.6 million in 2021 and averaged $541.2 million.
  • Per our database at Business Quant, Ionis Pharmaceuticals' Equity Average plummeted by 6522.5% in 2021 and then skyrocketed by 9768.37% in 2025.
  • Over the past 5 years, Ionis Pharmaceuticals' Equity Average (Quarter) stood at $651.1 million in 2021, then dropped by 10.37% to $583.6 million in 2022, then tumbled by 39.85% to $351.1 million in 2023, then surged by 78.14% to $625.4 million in 2024, then fell by 0.09% to $624.8 million in 2025.
  • Its Equity Average was $624.8 million in Q3 2025, compared to $553.7 million in Q2 2025 and $532.0 million in Q1 2025.